Express Pharma
Home  »  COVID-19 Updates  »  J&J makes submission to WHO for Emergency Use Listing of Janssen COVID-19 vaccine

J&J makes submission to WHO for Emergency Use Listing of Janssen COVID-19 vaccine

The data package delivered includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial

0 147
Read Article

Johnson & Johnson announced that Janssen-Cilag International NV has submitted for Emergency Use Listing (EUL) to the World Health Organization (WHO) for the investigational single-dose Janssen COVID-19 vaccine candidate. The data package delivered includes interim efficacy and safety results from the Phase 3 ENSEMBLE clinical trial. The Company’s rolling submission of clinical data to WHO is now complete.

“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our unwavering commitment to equitable access,” said Paul Stoffels, Vice Chairman of the Executive Committee and Chief Scientific Officer of Johnson & Johnson.  The EUL procedure streamlines the process by which new or unlicensed products can be assessed for use during public health emergencies by governments and UN procurement agencies. The EUL process expedites access to such products in many countries around the world and is also a prerequisite to supply vaccines to the new COVAX Facility, a global mechanism for pooled procurement and distribution of COVID-19 vaccines in 190 participating countries, including 92 lower-income countries.

In December 2020, the Company entered into an agreement in principle with Gavi, the Vaccine Alliance (Gavi) in support of the COVAX Facility. The Company and Gavi expect to enter into an Advance Purchase Agreement (APA) that would provide up to 500 million doses of the Janssen vaccine to COVAX through 2022.

The Company filed for Emergency Use Authorization (EUA) in the US on February 4, 2021, and submitted a Conditional Marketing Authorisation Application (cMAA) in the European Union on February 15, 2021. In addition, rolling submissions for the investigational single-dose COVID-19 vaccine have been initiated in several countries worldwide. The Company will continue to provide data on an ongoing basis in support of WHO prequalification for the Janssen COVID-19 vaccine candidate.

The Janssen investigational vaccine is compatible with standard vaccine distribution channels. If authorised, Janssen’s investigational single-dose vaccine is estimated to remain stable for two years at -20°C (-4°F), at least three months of which can be stored in most standard refrigerators at temperatures of 2°-8°C (36°F–46°F).

The Phase 3 ENSEMBLE study, a randomized, double-blind, placebo-controlled clinical trial in adults 18 years old and older, was designed to evaluate the safety and efficacy of the Janssen investigational vaccine in protecting against both moderate and severe COVID-19 disease, with assessment of efficacy as of day 14 and as of day 28 as co-primary endpoints. The Company announced topline efficacy and safety data from ENSEMBLE on January 29, 2021.

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image